Therapy-related myelodysplastic syndrome and myeloid leukemia

Lucy A. Godley, Richard A. Larson

Research output: Chapter in Book/Report/Conference proceedingChapter

3 Scopus citations


Therapy-related myeloid leukemia (t-MDS/t-AML) is a well-recognized clinical syndrome occurring as a late complication following cytotoxic therapy (1-4). The term “therapy-related” leukemia is based on a patient’s history of exposure to cytotoxic agents. Although a causal relationship is implied, the mechanism remains to be proven. These neoplasms are thought to be the direct consequence of mutational events induced by the prior therapy. Table 1 shows the various primary diagnoses and primary cytotoxic therapies received by 306 patients with therapy-related myeloid leukemia studied at the University of Chicago (3).

Original languageEnglish (US)
Title of host publicationMyelodysplastic Syndromes
Subtitle of host publicationPathobiology and Clinical Management, Second Edition
PublisherCRC Press
Number of pages22
ISBN (Electronic)9781420074406
ISBN (Print)1420074393, 9781420074390
StatePublished - Jan 1 2008

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Therapy-related myelodysplastic syndrome and myeloid leukemia'. Together they form a unique fingerprint.

Cite this